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ABSTRACT 32 
In Parkinson’s disease (PD), mitochondrial dysfunction associates with nigral dopamin-33 
ergic neuronal loss. Cholinergic neuronal loss co-occurs, particularly within a brainstem 34 
structure, the pedunculopontine nucleus (PPN). We isolated single cholinergic neurons 35 
from post-mortem PPNs of aged controls and PD patients. Mitochondrial DNA (mtDNA) 36 
copy number and mtDNA deletions were increased significantly in PD patients com-37 
pared to controls. Furthermore, compared to controls the PD patients had significantly 38 
more PPN cholinergic neurons containing mtDNA deletion levels exceeding 60%, a 39 
level associated with deleterious effects on oxidative phosphorylation. The current re-40 
sults differ from studies reporting mtDNA depletion in nigral dopaminergic neurons of 41 
PD patients.  42 
 43 
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1.   Introduction 55 
Parkinson’s disease (PD) patients typically present with tremor, bradykinesia and rigid-56 
ity, the onset and progression of which associate with selective loss of nigro-striatal do-57 
paminergic neurons.1 Interest has grown as to the role of non-dopaminergic neurotrans-58 
mission in PD. Cholinergic degeneration, affecting the basal forebrain, the nucleus ba-59 
salis of Meynert and a rostral brainstem structure called the pedunculopontine nucleus 60 
(PPN), associates with the onset and development of ‘axial’ signs and cognitive impair-61 
ment seen in PD patients.2-4 Surviving (but susceptible) cholinergic neurons in these nu-62 
clei contain aggregated α-synuclein fibrils, forming Lewy bodies and Lewy neurites, a 63 
neuropathological hallmark of PD.3  64 
 The links between mitochondria and PD patho-etiology are well studied.5 This 65 
commenced in the 1980s when the potent respiratory chain inhibitor 1-methyl-4-phenyl-66 
1,2,3,6-tetrahydropyridine (MPTP), serving as a prodrug to the neurotoxin MPP+, was 67 
shown to cause parkinsonism in illicit drug users,6 through to identification of complex-I-68 
mediated reactive oxygen species forming within PD brains7 and continuing with inher-69 
ited and somatic mitochondrial DNA (mtDNA) variants that were shown to affect PD 70 
risk.8-10 Additionally, changes in mitochondrial DNA copy number (mtCN) was shown to 71 
associate with PD pathology, with vulnerable dopaminergic neurons showing depleted 72 
levels of wild-type mtCN.11,12  73 
 Recently, we showed that several mitochondrial respiratory chain proteins are sig-74 
nificantly up-regulated in gamma-aminobutyric acid(GABA)ergic and glycinergic PPN 75 
neurons from PD post-mortem brains.3 Conversely, in the same patients, there was a 76 
marked reduction of these mitochondrial proteins in the cholinergic neurons of the PPN, 77 
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suggesting mitochondrial injury. Moreover, we observed a significant reduction in mito-78 
chondrial mass across all three neuronal types, with the most pronounced loss seen in 79 
PPN cholinergic neurons.3 Given the links between PPN cholinergic neuronal deteriora-80 
tion, mitochondrial function and the development of PD, we investigated the role of 81 
mtDNA maintenance and stability in cholinergic neurons from the PPN of PD patients 82 
and controls. 83 
2.   Materials and Methods 84 
Subjects: Post-mortem human brains (n=6 controls; n=6 PD; male:female ratio: 5:1) 85 
were obtained from the Newcastle Brain Tissue Resource in Newcastle upon Tyne, 86 
UK, which is covered by Newcastle University’s Human Tissue Authority license. Ethical 87 
approval was granted for this study in 2016 by the Newcastle and North Tyneside Local 88 
Research Ethics Committee. All tissue donors gave written informed consent during life. 89 
All cases were assessed locally by a Neuropathologist and met the UK-PD Society’s 90 
brain bank criteria for diagnosing PD. None of the control cases met such criteria and 91 
also did not meet operational criteria for diagnosing Alzheimer’s disease, with control 92 
brains that showed only minimal, age-related tau and β-amyloid pathology. The mean (± 93 
standard error of the mean (S.E.M.)) for post-mortem interval (PMI) was 21±4 hours (hrs) 94 
for PD cases and 20±3 hrs for controls. The mean (± S.E.M.) age of death was 76±3 95 
years for PD cases and 84±7 years for controls. Between PD and control cases 96 
there was no statistically significant differences in PMI or age of death 97 
(p=5.2×10-1 and p=2.3×10-1, respectively; independent Student’s t-test). The 98 
mean disease duration for the PD cohort was 8±2 years. 99 
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PPN identification: Serial sections (20 μm) were cut from the left hemisphere of PPN-100 
containing brain blocks, using a cryostat (Bright Instrument Company Ltd., UK). To dis-101 
tinguish the PPN, pairs of sections (first and last in series) for each case were stained 102 
with Haematoxylin and Eosin (H&E) (Fig. 1A) and Luxol Fast Blue (LFB) (Fig. 1B), using 103 
standard protocols. Paired stained sections were then used to define the PPN’s bound-104 
aries, noting neighboring neural structures, including the lateral lemniscus (LL), medial 105 
lemniscus (ML) and superior cerebellar decussation (SCD).13 106 
Single cell isolation: To immunohistochemically stain cholinergic neurons in PPN-con-107 
taining brain tissue sections, the sections were air-dried for 30 min at room temperature 108 
(RT) and then fixed for 20 min in 4% paraformaldehyde (PFA) dissolved in phosphate 109 
buffered saline (PBS). The sections were washed with PBS before blocking with 5% 110 
normal rabbit serum (S-5000; Vector laboratories, UK) for 30 min, then incubated for 2 111 
hrs at RT with a primary antibody detecting choline acetyltransferase (ChAT, polyclonal 112 
goat, 1:150; AB 144P, Millipore, USA). After further washing in PBS, the secondary anti-113 
body (peroxidase horse anti-goat, 1:200; PI-9500, Vector laboratories, UK) was applied 114 
for 1 hr at RT. Following washes in PBS, 3,3’,5,5’-tetramethylbenzidine (TMB) stabilized 115 
chromagen (Invitrogen, UK), a substrate of horseradish peroxidase that oxides to form a 116 
blue chromagen, was applied to the sections for 10 min at RT and then rinsed well with 117 
distilled water. All antibody and serum dilutions were made using Tris Buffered Saline 118 
(TBS). Individual PPN cholinergic neurons were isolated using the P.A.L.M. MicroBeam 119 
Laser-Capture Microdissection system coupled to an inverted Zeiss microscope (Axio-120 
vert 200M, Carl Zeiss, Germany), and individually placed into adhesive cap microfuge 121 
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tubes (Carl Zeiss, Germany) containing lysis buffer consisting of 50mM Tris-Hydrochlo-122 
ride with 1% Tween 20 (pH 8.0) and 20mg/ml proteinase K (Thermo Fisher Scientific, 123 
UK). Each lysis was immediately centrifuged at 13,000 revolutions/min and subse-124 
quently incubated at 55°C for 16 hrs, followed by incubation at 95°C for 10 min. In total, 125 
144 neurons were isolated (n=72 controls; n=72 PD). 126 
mtDNA analysis: Quantification of mtDNA was performed as previously described,14 via 127 
a probe-based11 multiplex Taqman quantitative polymerase chain reaction (qPCR) to 128 
amplify the mitochondrial genes MTND1 and MTND4. mtCN was calculated by absolute 129 
quantification of MTND1, using the standard curve method, with serial dilutions of PCR-130 
generated templates. PD and control samples (assayed in triplicate) were randomly as-131 
signed to each run to limit run-specific stratification. 132 
Statistical analysis: Data were analyzed using SPSS (version 22, SPSS Inc., USA) with 133 
data-appropriate tests (detailed in text). Statistical significance was set at p<5×10-2. The 134 
choice of which analyses to apply was based on the data type. A correlative analysis 135 
was used when two continuous variables were present, for example mtCN and PMI. A 136 
one-way ANOVA was used where there was greater than two categories whose means 137 
were to be compared, i.e. mtCN versus Braak stage (0-4). Data are expressed as the 138 
mean ± S.E.M. The raw mtCN data is available on request  139 
3.   Results 140 
Comparison of mtDNA levels from single PPN cholinergic neurons showed a signifi-141 
cant increase in mtCN in PD cases compared to controls (p=2.9×10-2, two-way 142 
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ANOVA, PD mean = 10,706±1,441 versus control mean = 7,017±825; Fig. 2A). Im-143 
portantly, no correlation was found between PMI and mtCN in either PD cases or con-144 
trols (p=5.1×10-1 and p=8.7×10-1 respectively, linear regression analysis). Furthermore, 145 
no significant association was detected between mtCN and PD duration (p=9.7×10-146 
1, linear regression analysis) nor mtCN and Braak stage (p=3.1×10-1, one-way 147 
ANOVA; Fig. 2B). 148 
mtDNA deletion levels were a lso  significantly  increased in PD cases com-149 
pared to controls (p=2.5×10-2, two-way ANOVA, PD mean = 21.60±3.04% versus con-150 
trol mean = 17.15±1.99%; Fig. 2C). Again, no correlation was found between PMI and 151 
mtDNA deletions in neither cases nor controls (p=9x10-2 and p=3.4x10-1 respectively, 152 
linear regression analysis). However, mtDNA deletion levels correlated with higher 153 
Braak staging in PD patients (p=3×10-3, one-way-ANOVA; Fig. 2D). Stratification of in-154 
dividual neurons into high- (i.e. >60% at which level they are likely to exhibit a pathologi-155 
cal phenotype8) and lower mtDNA deletion levels (i.e. <60%, and therefore less likely to 156 
exhibit a pathological phenotype), revealed that PD cases harbored a disproportionately 157 
higher number of PPN cholinergic neurons with high mtDNA deletion load compared 158 
to controls (p<1×10-4, Fisher’s exact test; Fig. 3A). 159 
Thus, unlike recent studies performed on substantia nigra pars compacta (SNpc) 160 
dopaminergic neurons taken from post-mortem PD brains, and which reported mtCN 161 
depletion,6,9,10,12 the current findings relating to single PPN cholinergic neurons showed 162 
significantly elevated mtCN and mtDNA deletion levels in PD patients compared to con-163 
trols. We investigated this relationship further by using linear regression analysis. A sig-164 
nificant negative correlation was observed between mtCN and mtDNA deletion levels in 165 
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neurons taken from controls (r=-2.5x10-1, p=4.9x10-2), this finding resulting from very 166 
few neurons having higher levels of mtDNA deletions. When all data points were in-167 
cluded, no significant association was detected between deletion levels and mtCN 168 
(r=5.4x10-2, p=6.7x10-1; Fig. 3A).  169 
An elevation in mtCN in response to the accumulation of mtDNA deletions might 170 
be considered evidence for cells’ ability to proliferate mtDNA in order to maintain a criti-171 
cal number of wild-type mtDNA molecules to support a variety of physiological pro-172 
cesses. This regression analysis was repeated, by excluding neurons containing lower 173 
deletion levels (30%), as at these lower levels the neuroprotective processes might not 174 
have been triggered yet, thereby inhibiting the ability to detect a correlation between the 175 
two variables. The exclusion of neurons with lower mtDNA deletion levels did not reveal 176 
a significant relationship between deletion levels and mtCN (r=0.23, p=4x10-1; Fig. 3B). 177 
Taken together, our study reveals an elevation of mtCN and mtDNA deletion levels in 178 
PD patients compared to controls; however, a correlation was not detected between 179 
mtCN and mtDNA deletion levels in the single cholinergic neurons of the PD patients.  180 
4.   Discussion 181 
This is the only study to date that characterizes mtCN and mtDNA deletion levels in cho-182 
linergic neurons of the PPN, a neuronal population that is highly vulnerable to cell death 183 
in PD patients. The aim was to better understand the role that mtDNA changes play in 184 
the loss of PPN cholinergic neurons in PD, which has been shown to be pivotal in the 185 
onset and progression of motor and non-motor PD symptoms.  186 
 Our investigations revealed that in remaining PPN cholinergic neurons of PD pa-187 
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tients mtCN is increased compared to controls. This is in contrast to studies which re-188 
ported decreased mtCN levels within remaining SNpc dopaminergic neurons in PD post-189 
mortem brains,8,11,12,15 suggesting for neuronal-type and brain region-specific responses 190 
to accumulation of mtDNA mutations in PD patients. However, similar to previous studies 191 
performed on SNpc dopaminergic neurons,8,11,12,15 our data indicate that mtDNA deletions 192 
are increased in PD patients compared to controls. Importantly, we show that in PD pa-193 
tients there is a substantial increase in the number of PPN cholinergic neurons contain-194 
ing >60% mtDNA deletion levels, making it highly likely that these neurons should mani-195 
fest a respiratory chain deficiency.8  196 
 Our data shows that cholinergic neurons in the PPN, in contrast to reports of deple-197 
tion in the SNpc of PD cases,8,11,12,15 appear to increase their mtCN in response to rising 198 
deletion levels. This raises the hypothesis that the PPN has a compensatory mechanism 199 
designed to maintain a pool of wild-type mtDNA molecules that is not present in the SNpc, 200 
or alternatively that the dopaminergic neurons of the SNpc are more vulnerable to rising 201 
mtDNA deletion levels than the cholinergic neurons of the PPN. The former appears to 202 
be supported by our data, as we detected a seemingly overall elevation in mtCN in the 203 
PD patients who also had higher deletion levels (Figs. 2A & B). This may reflect an ina-204 
bility by PPN cholinergic neurons to maintain the required level of wild-type mtDNA past 205 
the threshold deletion level, or might result from the smaller number of neurons with high 206 
levels of mtDNA deletions which we observed here. Nevertheless, this exploratory obser-207 
vation should be explored further in future studies.  208 
 Although not a conclusive indicator of PD, Braak staging indicates disease ad-209 
vancement.16 In this study, we identified a significant difference between high mtDNA 210 
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deletion levels and advanced Braak staging, supporting the hypothesis that mtDNA de-211 
letions within PPN cholinergic neurons contribute to PD progression. This is similar to 212 
SNpc dopaminergic neurons in PD patients, where Lewy body abundance, associated 213 
with advanced Braak staging, coincided with increased mtCN, which was hypothesized 214 
as a possible compensatory response against deficient levels of adenosine triphosphate 215 
(ATP).17 In the current study, we found no significant difference in PPN cholinergic neu-216 
ronal mtCN values between the different Braak stages; however, this is an area that 217 
merits additional investigation in future studies. 218 
 In conclusion, we show increased mtCN and mtDNA deletion levels within remain-219 
ing PPN cholinergic neurons in PD patients compared to controls. We further found sig-220 
nificantly more cholinergic neurons harboring mtDNA deletion levels that associate with 221 
a mitochondrial dysfunction in PD, compared to controls. These findings support the 222 
view that mtDNA deletions are frequent in PPN cholinergic neurons and that these 223 
might play a role in the death of these neurons in PD patients. Critically, the data sug-224 
gests that different brain regions and neurochemical cell types vary in their responses to 225 
accumulated mtDNA deletions in PD patients, since the data contrasts with prior obser-226 
vations relating to SNpc dopaminergic neurons.  227 
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Figure and table legends: 303 
Figure 1:  A low (2.5× air-based) objective lens was used to capture tiled images, (A) 304 
representing the most rostral and (B) immediately adjacent section, along the rostro-305 
caudal axis that cryostat sections were collected. The PPN and surrounding neural 306 
structures were visualized with (A) H&E and (B) LFB staining. Mapped outlines indicate 307 
the anatomical location of the PPN in relation to major surrounding structures, including 308 
the LL, ML and SCD. The insets show magnified (20× air-based objective) images of 309 
the (Ai) H&E and (Bi) LFB stained sections, illustrating the Ch5 cholinergic neurons of 310 
the PPN.18 Scale bars: (A, B) 500 μm and (Ai, Bi) 75 μm. (C) Isolation of individual cho-311 
linergic neurons from the PPN, using laser-assisted microdissection. (Ci) Prior to dis-312 
section, individual cholinergic neurons were viewed with a Brightfield inverted micro-313 
scope (Carl Zeiss) at high (40×) magnification. Neurons were collected based on ChAT 314 
immunoreactivity and typical morphology. Neurons were manually circumscribed by us-315 
ing the “draw shape” tool of the software interface. (Cii) Laser energy pulses were then 316 
applied to separate out an outlined neuron from the surrounding tissue. (D) Successful 317 
cell capture was confirmed by microscopically viewing the tube’s cap, shown at (Di) 5× 318 
and (Dii) 20× magnification. Scale bars: (Ci, Cii) 75 µm, (Di) 50 µm and (Dii) 75 µm. 319 
Figure 2: (A) A data scatter plot shows a significant increase in mtCN in PPN choliner-320 
gic neurons of PD compared to controls (p=2.9×10-2). There was no significant differ-321 
ence in these values between individual cases, although more stratification was ob-322 
served between the PD cases (p= 5.2×10-1). (B) A box plot shows no significant trend 323 
between increased mtCN and later Braak stage for the PD cohort (p=3.1×10-1). The er-324 
ror bars represent the 95% confidence interval (CI) of the mtCN values for each case. 325 
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Dots above the error bars represent values greater than the upper 95% CI. (C) A data 326 
scatter plot shows a significant increase in %mtDNA deletions in PD patients compared 327 
to controls (p=2.5×10-2), with no significant difference in such values between individual 328 
cases (p=7.8×10-2) in either the PD or control cohorts. Significantly more PPN choliner-329 
gic neurons harbored mtDNA deletions >60%, compared to controls (p<1×10-4). (D) A 330 
box plot of % mtDNA deletion against Braak stage shows a positive, statistically signifi-331 
cant relationship between mtDNA deletion levels and advanced Braak stage (p=3×10-3). 332 
The error bars represent the 95% CI of the mean percentage deletion value for each 333 
case. Dots above the error bars represent values greater than the upper 95% CI. 334 
Figure 3: The figure depicts the relationship between mtDNA deletion levels and mtCN 335 
for (A) all PPN cholinergic neurons taken from PD patients and controls, as well as (B) 336 
in PPN cholinergic neurons where mtDNA deletion levels exceeded 30%.  337 
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